Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells

NCT03236129 · clinicaltrials.gov ↗
PHASE3
Phase
UNKNOWN
Status
52
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Assistance Publique - Hôpitaux de Paris